81 related articles for article (PubMed ID: 16092593)
1. PSA and clinical responses to celecoxib in a patient with prostate cancer and bone metastases.
Sonpavde G; Hayes TG
Mayo Clin Proc; 2005 Aug; 80(8):1100-1. PubMed ID: 16092593
[No Abstract] [Full Text] [Related]
2. Inflammatory pathogenesis of prostate cancer and celecoxib.
Mathew P
J Clin Oncol; 2010 Apr; 28(12):e197; author reply e198. PubMed ID: 20177014
[No Abstract] [Full Text] [Related]
3. Cyclooxygenase-2 inhibitor suppresses tumour progression of prostate cancer bone metastases in nude mice.
Garcia M; Velez R; Romagosa C; Majem B; Pedrola N; Olivan M; Rigau M; Guiu M; Gomis RR; Morote J; Reventós J; Doll A
BJU Int; 2014 May; 113(5b):E164-77. PubMed ID: 24127882
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of celecoxib in prostate-specific antigen recurrent prostate cancer after definitive radiation therapy or radical prostatectomy.
Pruthi RS; Derksen JE; Moore D; Carson CC; Grigson G; Watkins C; Wallen E
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2172-7. PubMed ID: 16609031
[TBL] [Abstract][Full Text] [Related]
5. The design of a randomized, placebo-controlled trial of celecoxib in preprostatectomy men with clinically localized adenocarcinoma of the prostate.
Heath EI; DeWeese TL; Partin AW; De Marzo AM; Groopman JD; Nelson WG; Piantadosi SA; Lieberman R; Carducci MA
Clin Prostate Cancer; 2002 Dec; 1(3):182-7. PubMed ID: 15046694
[No Abstract] [Full Text] [Related]
6. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model.
Narayanan BA; Narayanan NK; Pittman B; Reddy BS
Clin Cancer Res; 2004 Nov; 10(22):7727-37. PubMed ID: 15570007
[TBL] [Abstract][Full Text] [Related]
7. Adenocarcina of the mouse prostate growth inhibition by celecoxib: downregulation of transcription factors involved in COX-2 inhibition.
Narayanan BA; Narayanan NK; Pttman B; Reddy BS
Prostate; 2006 Feb; 66(3):257-65. PubMed ID: 16175586
[TBL] [Abstract][Full Text] [Related]
8. A randomized controlled trial investigating the effects of celecoxib in patients with localized prostate cancer.
Sooriakumaran P; Coley HM; Fox SB; Macanas-Pirard P; Lovell DP; Henderson A; Eden CG; Miller PD; Langley SE; Laing RW
Anticancer Res; 2009 May; 29(5):1483-8. PubMed ID: 19443354
[TBL] [Abstract][Full Text] [Related]
9. A gene expression profiling approach assessing celecoxib in a randomized controlled trial in prostate cancer.
Sooriakumaran P; Macanas-Pirard P; Bucca G; Henderson A; Langley SE; Laing RW; Smith CP; Laing EE; Coley HM
Cancer Genomics Proteomics; 2009; 6(2):93-9. PubMed ID: 19451093
[TBL] [Abstract][Full Text] [Related]
10. [The role of PSA in prostatic adenocarcinoma].
Manca GP
Minerva Med; 1990 Apr; 81(4):261-4. PubMed ID: 1692981
[TBL] [Abstract][Full Text] [Related]
11. Atorvastatin and celecoxib inhibit prostate PC-3 tumors in immunodeficient mice.
Zheng X; Cui XX; Avila GE; Huang MT; Liu Y; Patel J; Kong AN; Paulino R; Shih WJ; Lin Y; Rabson AB; Reddy BS; Conney AH
Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5480-7. PubMed ID: 17875778
[TBL] [Abstract][Full Text] [Related]
12. A multicenter phase II trial of losoxantrone (DuP-941) in hormone-refractory metastatic prostate cancer.
Huan SD; Natale RB; Stewart DJ; Sartiano GP; Stella PJ; Roberts JD; Symes AL; Finizio M
Clin Cancer Res; 2000 Apr; 6(4):1333-6. PubMed ID: 10778959
[TBL] [Abstract][Full Text] [Related]
13. Bone metastases from prostate cancer without elevated prostate-specific antigen levels: diagnosis by anti-PSA immunostaining.
Berthelot JM; Gouin F; Denis M; Nomballais MF; Maugars Y; Blaive-Cervi S; Prost A
Rev Rhum Engl Ed; 1995 Jan; 62(1):54-5. PubMed ID: 7540487
[No Abstract] [Full Text] [Related]
14. The effect of cyclooxygenase-2 (COX-2) inhibition on human prostate cancer induced osteoblastic and osteolytic lesions in bone.
Gamradt SC; Feeley BT; Liu NQ; Roostaeian J; Lin YQ; Zhu LX; Sharma S; Dubinett SM; Lieberman JR
Anticancer Res; 2005; 25(1A):107-15. PubMed ID: 15816526
[TBL] [Abstract][Full Text] [Related]
15. Cyclooxygenase-2 selective inhibitors and prostate cancer: what is the clinical benefit?
DuBois RN
J Clin Oncol; 2006 Jun; 24(18):2691-3. PubMed ID: 16782907
[No Abstract] [Full Text] [Related]
16. Impact of celecoxib on capecitabine tolerability and activity in pretreated metastatic breast cancer: results of a phase II study with biomarker evaluation.
Fabi A; Metro G; Papaldo P; Mottolese M; Melucci E; Carlini P; Sperduti I; Russillo M; Gelibter A; Ferretti G; Tomao S; Milella M; Cognetti F
Cancer Chemother Pharmacol; 2008 Sep; 62(4):717-25. PubMed ID: 18071704
[TBL] [Abstract][Full Text] [Related]
17. Case records of the Massachusetts General Hospital. Case 16-2011. A 67-year-old man with recurrent prostate cancer.
Smith MR; Zietman AL; Finkelstein JS; Wu CL
N Engl J Med; 2011 May; 364(21):2044-51. PubMed ID: 21612474
[No Abstract] [Full Text] [Related]
18. COX-2 inhibitors in prostate cancer treatment--hold your horses?
Cheung AS; Grossmann M
Asian J Androl; 2012 Jul; 14(4):518-9. PubMed ID: 22635163
[No Abstract] [Full Text] [Related]
19. Dimethyl celecoxib as a novel non-cyclooxygenase 2 therapy in the treatment of non-small cell lung cancer.
Backhus LM; Petasis NA; Uddin J; Schönthal AH; Bart RD; Lin Y; Starnes VA; Bremner RM
J Thorac Cardiovasc Surg; 2005 Nov; 130(5):1406-12. PubMed ID: 16256796
[TBL] [Abstract][Full Text] [Related]
20. Antitumoral effect of celecoxib in hepatocellular carcinoma.
Malka D; Pacault V; De Baere T; Ducreux M; Boige V
J Clin Oncol; 2005 Jul; 23(21):4805-6. PubMed ID: 16034068
[No Abstract] [Full Text] [Related]
[Next] [New Search]
